Verici Dx Plc (GB:VRCI) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Verici Dx Plc, a developer of diagnostic tests for organ transplants, has successfully completed the technology transfer for pre-transplant prognostic testing to Thermo Fisher Scientific, as per their 2023 licensing and commercialization agreement. This achievement allows Thermo Fisher Scientific to develop a Laboratory Developed Test in their own labs and triggers an additional milestone payment for Verici Dx. The CEO of Verici Dx expressed satisfaction with the collaboration, anticipating benefits for patients and advancements in the field of organ transplantation.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.